Interpace Biosciences, Inc.
IDXG
$0.95
$0.077.35%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -28.78% | -23.33% | 13.14% | 21.88% | 35.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.78% | -23.33% | 13.14% | 21.88% | 35.44% |
| Cost of Revenue | -24.49% | -6.61% | 7.19% | 20.66% | 6.52% |
| Gross Profit | -31.17% | -32.41% | 16.78% | 22.35% | 59.51% |
| SG&A Expenses | -23.29% | 10.80% | 6.01% | 21.89% | 16.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.84% | 3.08% | 6.86% | 21.11% | 9.90% |
| Operating Income | -50.24% | -117.78% | 64.18% | 24.27% | 14,481.25% |
| Income Before Tax | -43.25% | -121.19% | 117.16% | 45.44% | 436.26% |
| Income Tax Expenses | -375.00% | -- | 350.00% | -260.00% | 0.00% |
| Earnings from Continuing Operations | -42.49% | -121.23% | 116.01% | 46.21% | 432.95% |
| Earnings from Discontinued Operations | -21.95% | -44.59% | -2.88% | -78.67% | 4.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.64% | -126.26% | 132.63% | 41.63% | 372.96% |
| EBIT | -50.24% | -117.78% | 64.18% | 24.27% | 14,481.25% |
| EBITDA | -47.38% | -113.60% | 65.01% | 24.49% | 965.63% |
| EPS Basic | -46.03% | -125.98% | 130.00% | 16.84% | 368.28% |
| Normalized Basic EPS | -43.68% | -120.96% | 114.74% | 42.42% | 430.74% |
| EPS Diluted | -90.46% | -126.16% | -65.37% | -89.66% | 368.28% |
| Normalized Diluted EPS | -90.92% | -121.08% | -65.61% | -87.37% | 428.50% |
| Average Basic Shares Outstanding | 0.73% | 1.07% | 1.14% | 1.75% | 1.71% |
| Average Diluted Shares Outstanding | 526.16% | 0.50% | 531.93% | 1,045.71% | 2.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |